Is SPRAVATO® Taken With an Oral Antidepressant?

A group of friends laughs together outside the historic courthouse downtown, reconnecting with life through SPRAVATO treatment in Weatherford, TX.

There is a particular kind of confusion that can come with a new treatment option. You may have tried antidepressants before. You may have changed doses, waited through side effects, or started over with another prescription. Then you hear about SPRAVATO®, and one question rises quickly: if it works differently, why might I still take an oral antidepressant?

It is a fair question. It deserves a clear answer.

SPRAVATO® is not designed as a simple replacement for every medication that came before it. Much of the pivotal research, and many treatment plans, involve SPRAVATO® alongside an oral antidepressant. At the same time, FDA labeling permits SPRAVATO® as monotherapy for adults with treatment-resistant depression. The right approach depends on your diagnosis, treatment history, current medications, and clinical needs.

At Vigeo Wellness, we want you to understand the whole picture before deciding whether to explore care with us. Depression can make every next step feel heavy. Clear information can make that step more manageable.

This article is educational and is not medical advice. It does not replace an individualized evaluation or guidance from a qualified clinician who knows your medical and psychiatric history.

SPRAVATO® can be one part of a thoughtful treatment plan

SPRAVATO® is the brand name for esketamine, a nasal spray administered in a certified healthcare setting. It is FDA-approved for certain adults with depression, including treatment-resistant depression.

Many of the studies that established its role in treatment-resistant depression evaluated esketamine nasal spray with a newly initiated oral antidepressant. In one major trial, participants received esketamine plus an oral antidepressant or placebo nasal spray plus an oral antidepressant. The findings support esketamine studied alongside an antidepressant in treatment-resistant depression (Popova et al., 2019).

That evidence matters, but it does not mean that an oral antidepressant is universally required for every adult with treatment-resistant depression. FDA labeling also permits SPRAVATO® monotherapy for adults with treatment-resistant depression, and a more recent trial has examined esketamine monotherapy in adults with treatment-resistant depression (Janik et al., 2025).

The oral medication and SPRAVATO® do not do the same job in the same way. Traditional antidepressants commonly affect neurotransmitter systems such as serotonin, norepinephrine, or dopamine. Esketamine acts through the glutamate system, an area of brain signaling that has become important in modern depression research. Glutamatergic treatments have a distinct clinical rationale from many conventional antidepressant approaches (McIntyre et al., 2024).

Different does not mean disconnected. When SPRAVATO® and an oral antidepressant are used together, they are intended to be part of one thoughtful plan.

For some people, that plan begins after several prior medications have not brought enough relief. Our work with treatment-resistant depression starts with listening carefully to that history. We want to know what you have tried, what changed, what did not, and what your current care team has observed.

Why this is not simply switching medications

A medication switch often means stopping one antidepressant, safely tapering when needed, and starting another. SPRAVATO® can be approached differently. Depending on your individual plan, it may be used with an oral antidepressant, or it may be considered as monotherapy when clinically appropriate under its FDA-approved labeling.

If an oral antidepressant is part of your plan, your prescribing clinician may recommend beginning a new one, continuing one that is appropriate, or making another adjustment based on your history and medical needs. Those decisions are individual. They should be made carefully.

We do not view a medication list as a scorecard. A long list does not mean you failed. It tells part of the story of how persistent depression has been for you. It can also help clarify what a reasonable next step may be.

Research has examined whether ongoing combined treatment can help maintain improvement for some patients. In a relapse-prevention trial, continued esketamine plus an oral antidepressant was associated with lower relapse risk during maintenance among participants who had achieved stable response or remission (Daly et al., 2019). That finding does not predict what will happen for any one person. It does help explain why combination treatment remains an important clinical approach.

Supervised administration is part of the treatment

SPRAVATO® is not picked up at a pharmacy and taken at home. Each session takes place under clinical supervision. That structure matters.

After using the nasal spray, you remain with us for monitoring. SPRAVATO® can cause sedation, dissociation, dizziness, and temporary increases in blood pressure. Some people describe dissociation as feeling detached from their thoughts, body, or surroundings. It can be unsettling, even when it passes.

We create space for the experience. We monitor you. We make sure you are ready to leave safely.

You will need transportation home after treatment. You should not drive or operate machinery until the next day after a restful sleep. We will review practical instructions before your first session, including medication considerations, food and drink guidance, and what to expect afterward.

Longer-term studies of esketamine plus oral antidepressants have continued to examine tolerability and safety over time, including the importance of ongoing monitoring during treatment (Wajs et al., 2020). Monitoring is not an extra step around care. It is part of care.

How we decide whether SPRAVATO® may fit

Depression is not one identical experience. Neither is treatment.

Before recommending SPRAVATO®, we review your psychiatric history, current medications, medical conditions, past treatment experiences, and safety needs. We also consider whether the symptoms you are living with fit the treatment indication. We may coordinate with your existing psychiatric provider when appropriate.

Our approach is measured. We do not assume a new treatment is automatically the right treatment. We also do not dismiss the possibility because previous approaches have fallen short.

For readers seeking support closer to Tarrant County, our Fort Worth depression care and our Weatherford depression support begin with the same principle: your story matters. A diagnosis alone does not explain your needs, your risks, or your hopes for treatment.

We also talk honestly about practical matters. Treatment involves appointments, observation time, transportation planning, and continued communication. These details can feel ordinary. They are still important. Good care has to fit the reality of your life as much as possible.

If you are comparing different services, our ketamine treatment FAQs can help you understand that separate treatment option. Ketamine for psychiatric uses is off-label, and it is evaluated differently from SPRAVATO®.

Questions people often ask

Can I stop my oral antidepressant once I begin SPRAVATO®?

Do not stop, start, or change psychiatric medication on your own. Some people receive SPRAVATO® with an oral antidepressant, while FDA labeling permits SPRAVATO® monotherapy for adults with treatment-resistant depression. Any medication adjustment should come from the clinician managing your treatment, with attention to safety and your individual history.

Does SPRAVATO® work immediately?

Some research has found rapid changes in depressive symptoms for certain people, but treatment response varies. In studies involving adults with severe depression and active suicidal ideation, symptoms changed rapidly for some participants when esketamine was added to comprehensive standard care (Fu et al., 2020). Rapid change is not a guarantee, and it does not replace ongoing treatment, support, or safety planning.

Is SPRAVATO® right for every kind of depression?

No. It is not appropriate for everyone with depression. Eligibility depends on diagnosis, treatment history, medical considerations, current medications, and clinical judgment. We will talk through those questions directly rather than offering a one-size-fits-all answer.

What if I am in crisis right now?

If you are in immediate danger, call 911 or go to the nearest emergency room. If you are having thoughts of suicide or need urgent emotional support, the 988 Suicide and Crisis Lifeline is available by call or text, 24 hours a day (988 Suicide and Crisis Lifeline, n.d.). You deserve support now, not later.

The point is not to do more. It is to treat more thoughtfully.

Taking SPRAVATO® with an oral antidepressant can sound complicated at first. For many people, that combination reflects a deliberate model of care supported by pivotal research. For eligible adults with treatment-resistant depression, monotherapy may also be an option under FDA labeling. The details depend on the person, not a formula.

We believe you deserve to know why each part of your plan is there.

If you are considering SPRAVATO® and want to talk through your treatment history, we invite you to reach out to Vigeo Wellness. We will take the questions seriously. We will discuss what care may involve, and whether it may be a reasonable next step for you.

Works Cited

1. Popova V, et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. https://pubmed.ncbi.nlm.nih.gov/31109201/

2. Janik A, et al. Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/40601310/

3. McIntyre RS, et al. Glutamatergic Modulators for Major Depression from Theory to Clinical Use. https://pubmed.ncbi.nlm.nih.gov/39150594/

4. Daly EJ, et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/31166571/

5. Wajs E, et al. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2). https://pubmed.ncbi.nlm.nih.gov/32316080/

6. Fu DJ, et al. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I). https://pubmed.ncbi.nlm.nih.gov/32412700/

7. 988 Suicide and Crisis Lifeline. https://988lifeline.org/

Disclaimer

This article is for educational purposes only and is not a substitute for individualized evaluation, diagnosis, or treatment from a qualified healthcare professional.

Our Locations

Fortworth, TX

906 W Cannon St Suite 100
Fort Worth, TX 76104

Weatherford, TX

1800 Lone Oak Rd Suite 10
Weatherford, TX 76086

Share Post :

Contact Us Today